Cyclic guanosine monophosphate (cGMP) is a unique second messenger molecule formed
in different cell types and tissues. cGMP targets a variety of downstream effector molecules …

BACKGROUND Deficient nitric oxide-soluble guanylate cyclase-cyclic guanosine
monophosphate signaling results from endothelial dysfunction and may underlie impaired …

The role of obesity in the pathogenesis of heart failure (HF), and in particular HF with
preserved ejection fraction (HFpEF), has drawn significant attention in recent years. The …

Background—Heart failure with preserved ejection fraction (HFpEF) is associated with
substantial morbidity and mortality. Existing data on cardiac structure and function in HFpEF …

Normal cardiac function requires that intracellular Ca2+ concentration be reduced to low
levels in diastole so that the ventricle can relax and refill with blood. Heart failure is often …

Hypertension constitutes a major risk factor for heart failure with preserved ejection fraction
(HFpEF). HFpEF is a prevalent clinical syndrome with increased cardiovascular morbidity …

Background—Abnormalities in cardiac structure and function in heart failure with preserved
ejection fraction may help identify patients at particularly high risk for cardiovascular …

Background: There is no effective medical treatment for heart failure with preserved ejection
fraction (HFpEF). Increases in pulmonary capillary wedge pressure (PCWP) develop in …

In contrast to the wealth of proven therapies for heart failure with reduced ejection fraction
(HFrEF), therapeutic efforts in the past have failed to improve outcomes in heart failure with …

Heart failure with preserved ejection fraction (HFpEF) is now recognized as a major and
growing public health problem worldwide. Yet significant uncertainties still surround its …